These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 9166535)

  • 21. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.
    Asmis TR; Ding K; Seymour L; Shepherd FA; Leighl NB; Winton TL; Whitehead M; Spaans JN; Graham BC; Goss GD;
    J Clin Oncol; 2008 Jan; 26(1):54-9. PubMed ID: 18165640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction chemotherapy in non small cell lung cancer stage IIIa-b and IV and second-line treatment.
    Stathopoulos GP; Dafni UG; Malamos NA; Rigatos S; Kouvatseas G; Moschopoulos N
    Anticancer Res; 1999; 19(4C):3543-8. PubMed ID: 10629650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer].
    Li DX; Chen XB
    Ai Zheng; 2002 Apr; 21(4):412-5. PubMed ID: 12452023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The quality of life after chemotherapy in advanced non-small cell lung cancer patients].
    Słowik-Gabryelska A; Szczepanik A; Kalicka A
    Pol Merkur Lekarski; 1999 Jan; 6(31):18-22. PubMed ID: 10344148
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
    Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
    J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of p53 and glutathione S-transferase-pi relates to clinical drug resistance in non-small cell lung cancer.
    Nakanishi Y; Kawasaki M; Bai F; Takayama K; Pei XH; Takano K; Inoue K; Osaki S; Hara N; Kiyohara C
    Oncology; 1999 Nov; 57(4):318-23. PubMed ID: 10575319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased expression levels of p53 correlate with good response to cisplatin-based chemotherapy in non-small cell lung cancer.
    Oshita F; Nishio K; Kameda Y; Mitsuda A; Ikehara M; Tanaka G; Yamada K; Nomura I; Noda K; Arai H; Ito H; Nakayama H
    Oncol Rep; 2000; 7(6):1225-8. PubMed ID: 11032919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma.
    Yasuda H; Nakayama K; Watanabe M; Suzuki S; Fuji H; Okinaga S; Kanda A; Zayasu K; Sasaki T; Asada M; Suzuki T; Yoshida M; Yamanda S; Inoue D; Kaneta T; Kondo T; Takai Y; Sasaki H; Yanagihara K; Yamaya M
    Clin Cancer Res; 2006 Nov; 12(22):6748-57. PubMed ID: 17121895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers.
    Harada T; Ogura S; Yamazaki K; Kinoshita I; Itoh T; Isobe H; Yamashiro K; Dosaka-Akita H; Nishimura M
    Cancer Sci; 2003 Apr; 94(4):394-9. PubMed ID: 12824911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Posttranslational p53 phosphorylation in non small cell lung cancer cells after radio/chemotherapy].
    Hołownia A; Mróz RM; Kozłowski M; Chyczewska E; Laudański J; Chyczewski L; Braszko JJ
    Pneumonol Alergol Pol; 2007; 75(3):241-50. PubMed ID: 17966099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
    Gregorc V; Ludovini V; Pistola L; Darwish S; Floriani I; Bellezza G; Sidoni A; Cavaliere A; Scheibel M; De Angelis V; Bucciarelli E; Tonato M
    Lung Cancer; 2003 Jan; 39(1):41-8. PubMed ID: 12499093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer.
    Kawasaki M; Nakanishi Y; Kuwano K; Takayama K; Kiyohara C; Hara N
    Eur J Cancer; 1998 Aug; 34(9):1352-7. PubMed ID: 9849416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [p53 and HER-2/neu expression in relation to chemotherapy in non-small cell lung cancer patients].
    Fijołek J
    Pneumonol Alergol Pol; 2003; 71(7-8):365-70. PubMed ID: 15052971
    [No Abstract]   [Full Text] [Related]  

  • 34. The predictive value of neuroendocrine markers and p53 for response to chemotherapy and survival in patients with advanced non-small cell lung cancer.
    Gajra A; Tatum AH; Newman N; Gamble GP; Lichtenstein S; Rooney MT; Graziano SL
    Lung Cancer; 2002 May; 36(2):159-65. PubMed ID: 11955650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TopBP1 contributes to the chemoresistance in non-small cell lung cancer through upregulation of p53.
    Lv Y; Huo Y; Yu X; Liu R; Zhang S; Zheng X; Zhang X
    Drug Des Devel Ther; 2016; 10():3053-3064. PubMed ID: 27729767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer.
    Wang SS; Zimmermann M; Zhang H; Lin TY; Malfatti M; Haack K; Turteltaub KW; Cimino GD; de Vere White R; Pan CX; Henderson PT
    Int J Cancer; 2017 Aug; 141(3):604-613. PubMed ID: 28437852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human non-small cell lung cancer: p53 protein accumulation is an early event and persists during metastatic progression.
    Walker C; Dixon GR; Myskow M
    J Pathol; 1995 Jul; 176(3):319-20. PubMed ID: 7674094
    [No Abstract]   [Full Text] [Related]  

  • 38. Complete sequence of p53 gene in 20 patients with lung cancer: comparison with chemosensitivity and immunohistochemistry.
    Brattström D; Bergqvist M; Lamberg K; Kraaz W; Scheibenflug L; Gustafsson G; Inganäs M; Wagenius G; Brodin O
    Med Oncol; 1998 Dec; 15(4):255-61. PubMed ID: 9951689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High expression of integrin beta1 and p53 is a greater poor prognostic factor than clinical stage in small-cell lung cancer.
    Oshita F; Kameda Y; Hamanaka N; Saito H; Yamada K; Noda K; Mitsuda A
    Am J Clin Oncol; 2004 Jun; 27(3):215-9. PubMed ID: 15170136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thallium-201 SPECT in advanced non-small cell lung cancer: in relation with chemotherapeutic response, survival, distant metastasis and p53 status.
    Cermik TF; Yüksel M; Karlikaya C; Doğanay L; Türe M; Berkarda S
    Ann Nucl Med; 2003 Jul; 17(5):369-74. PubMed ID: 12971634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.